Denneroll vs. ChiroLux: Cervical Orthotic Patent Case Dismissed After 501 Days

Case Overview

In a patent infringement action that ran for nearly 17 months before reaching a negotiated resolution, Denneroll Holdings Pty, Limited and Denneroll Industries International Pty, Limited filed suit against ChiroLux LLC in the U.S. District Court for the Eastern District of Washington, asserting infringement of U.S. Patent No. 11,419,440 B2 — a patent covering cervical orthotic device technology.

The case, docketed as 2:24-cv-00176, concluded on October 7, 2025, with a Joint Stipulation of Dismissal with Prejudice, with each party bearing its own costs and attorneys’ fees. No damages award or injunctive relief was disclosed, suggesting the parties reached a private resolution before trial.

For patent attorneys, IP professionals, and R&D leaders operating in the medical device and chiropractic product space, this case offers meaningful signals about how cervical orthotic patent disputes are litigated and resolved — and what strategic decisions drive parties toward negotiated exits rather than adjudicated verdicts.

The Parties

The Patent at Issue

This case involved **U.S. Patent No. 11,419,440 B2** (application number 16/107,840), covering technology related to cervical orthotic devices designed to restore or enhance cervical lordosis — the natural curvature of the neck. The patent protects structural and functional innovations in Denneroll’s spinal correction products.

• • US 11,419,440 B2 — Cervical orthotic device technology

Litigation Timeline & Procedural History

The case was filed in the U.S. District Court for the Eastern District of Washington, presided over by Chief Judge Thomas O. Rice. The 501-day duration from filing to dismissal is notable: long enough to have survived initial pleading challenges and likely entered discovery or early motion practice, yet concluding before any dispositive rulings or trial.

The Verdict & Legal Analysis

Outcome

The case was dismissed with prejudice pursuant to a joint stipulation agreed to by both parties. Each side bears its own costs and attorneys’ fees — an arrangement that deliberately avoids any finding of prevailing-party status. No damages figure was disclosed publicly, and no injunctive relief was entered by the court.

A dismissal with prejudice means Denneroll cannot re-file the same claims against ChiroLux on the same patent and accused products. This is a permanent resolution, not a procedural pause.

Key Legal Issues

The dismissal before any judicial ruling on the merits leaves the legal record intentionally silent on claim construction or validity. However, the defendant’s own marketing language, describing its product as “cervical denneroll style,” likely played a significant role in the plaintiff’s infringement narrative, underscoring the risk of inadvertent admissions in product positioning.

Industry & Competitive Implications

The chiropractic and spinal orthotic device market is a niche but competitive space where product differentiation is tightly tied to patented technology. Denneroll’s willingness to litigate in U.S. federal court — despite being an Australian entity — signals a proactive global IP enforcement strategy for its cervical orthotic patent portfolio.

For competitors in this market, the case sends a clear deterrent signal: Denneroll will pursue infringement claims even against smaller U.S. companies. The approximately 17-month litigation trajectory also demonstrates that resolving these disputes before trial is possible, but not quick or inexpensive.

The broader trend this case reflects is a growing pattern of medical device and therapeutic product patent enforcement by international IP holders in U.S. courts, particularly where U.S. market penetration by accused products is commercially significant. Companies developing cervical lordosis correction devices, spinal orthotics, or adjacent therapeutic hardware should treat U.S. Patent No. 11,419,440 B2 as a live enforcement risk.

From a licensing perspective, the undisclosed resolution terms may represent a licensing or cross-licensing arrangement — a common outcome where the accused product has genuine commercial merit but requires IP authorization to continue operating in the market.

Frequently Asked Questions

What patent was involved in Denneroll v. ChiroLux?

U.S. Patent No. 11,419,440 B2, covering cervical orthotic device technology. The application number is 16/107,840.

Why was the case dismissed with prejudice?

The parties filed a Joint Stipulation of Dismissal with Prejudice under Rule 41(a)(1)(A)(ii), suggesting a private resolution. The court did not adjudicate the merits of infringement or validity.

How might this case affect cervical orthotic patent litigation?

While non-precedential, the case signals active U.S. enforcement of Denneroll’s patent portfolio and highlights the risk of product marketing language that mirrors a competitor’s brand identity.